S&P Futures
5,886.00 -6.50 (-0.11%) Dow Futures
43,035.00 -134.00 (-0.31%) Nasdaq Futures
20,510.75 -31.25 (-0.15%) Russell 2000 Futures
2,244.30 -1.90 (-0.08%) Crude Oil
72.24 +0.15 (+0.21%) Gold
2,758.20 -1.60 (-0.06%)
Context Therapeutics Inc. (CNTX)
After hours:
| Previous Close | 2.0600 |
| Open | 2.0300 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.0000 - 2.1500 |
| 52 Week Range | 0.7700 - 2.7500 |
| Volume | |
| Avg. Volume | 180,493 |
| Market Cap | 149.997M |
| Beta (5Y Monthly) | 2.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9600 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.63 |
GlobeNewswireContext Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced a poster regarding the Company’s clinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, being held November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX. Presentation Details:
GlobeNewswireBioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $118.5 million, plus royalties on net sales Context anticipated IND filing for BA3362 in mid-2026 SAN DIEGO and PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (“BioAtla”) (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the developme
